N
N

Novartis


Balita

Novartis to spin off generics business Sandoz next year

* Co has not received formal offers for Sandoz to date * Announcement of spin-off not a surprise - analysts * Novartis shares inch lower in afternoon trading By Natalie Grover ZURICH/LONDON, Aug 25 (Reuters) - Novartis NOVN.S plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.
N
R

Novartis says lung cancer drug canakinumab failed phase III trial

ZURICH, Aug 15 (Reuters) - Novartis NOVN.S said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial. The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said. Reporting by John Revill; Editing by Christian Schmollinger
N

Novartis to cut thousands of jobs in global revamp - paper

ZURICH, April 12 (Reuters) - Swiss drugmaker Novartis NOVN.S will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss newspaper Tages-Anzeiger reported on Tuesday, citing unnamed company sources. More than 100 jobs could also disappear at Novartis's Swiss sites in Rotkreuz and Basel, the paper reported.
N

UK Stocks-Factors to watch on Dec. 22

Dec 22 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.28%. * METRO BANK: The Bank of England's Prudential Regulation Authority has fined Metro Bank METRO.L 5.38 million pounds ($7.13 million) for failures in its regulatory reporting governance and controls, it said. * TAYLOR WIMPEY: UK's third-largest homebuilder Taylor Wimpey TW.L will drop contract terms that lock leaseholders into rents that double every 10 years, ending a year-long pro
A
N
P
B
R
T
U

Novartis CEO says Sandoz attracting interest - paper

ZURICH, Dec 10 (Reuters) - Novartis's NOVN.S potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday. The Swiss pharmaceuticals company raised the prospect of divesting Sandoz in October after years of revamping the business, as price pressures mount in the off-patent drug sector.
N

Novartis chairman says all options open for Sandoz unit - report

ZURICH, Nov 30 (Reuters) - Novartis NOVN.S is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday. Asked whether Novartis could merge Sandoz with either Israel's Teva TEVA.TA or U.S.-based Viatris VTRS.O or divest it, Joerg Reinhardt said: "All options are open for us." He said listing Sandoz on the Swiss stock exchange, a merger or keeping the business were all possible.
N
T

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

ZURICH, Nov 26 (Reuters) - Roche ROG.S shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's NOVN.S nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.
N
R

Dovish Fed taper, now hawkish BoE?

Nov 4 - A look at the day ahead from Danilo Masoni. Well done Mr. Powell! The Federal Reserve Chair looks to have managed to sell the dialling back of the bank's massive stimulus programme as a dovish taper and investors can now return to the joys of stock markets at record highs. The U.S. policy package contained no nasty surprises — the $15 billion reduction in monthly purchases was consensual and the inflation is "transitory" message was reiterated.
C
N
R
S
U

Upbeat earnings push European stocks close to record highs

* STOXX 600 at strongest close since record high in August * Reckitt soars on forecast lift * Logitech slides after results * Travel and leisure stocks lead gains (Updates to market close) By Anisha Sircar and Ambar Warrick Oct 26 (Reuters) - European stocks hit a more-than two-month high on Tuesday, ending just below record levels as strong results from UBS, Reckitt Benckiser and others added to overall optimism about the third-quarter earnings season.
L
N
U
G
E
F
U

Upbeat earnings pull European stocks higher; Reckitt gains on forecast lift

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) Oct 26 (Reuters) - European stocks inched toward record levels on Tuesday as strong results from UBS, Reckitt Benckiser and others added to overall optimism about the third-quarter earnings season. The pan-European STOXX 600 .STOXX rose 0.2% as of 0714 GMT after Asian shares edged higher, drawing comfort from fresh record highs for Wall Street indexes.
L
N
U
G
E
F
U



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.